Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Ataraxis AI›
News
AddedJun 26, 2026
UpdatedJun 26, 2026
Ataraxis AI

Ataraxis AI

Series A

Ataraxis AI develops AI-powered precision medicine tools for cancer care, integrating digital pathology and clinical data to personalize treatment selection.

HQ
New York, NY, US
Founded
2023
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Website

Latest News About Ataraxis AI

Ataraxis AI Launches Ataraxis Breast NEO, a New AI Test Predicting Response to Neoadjuvant Therapy in Breast Cancer

Business Wire

Ataraxis AI Launches Ataraxis Breast NEO, a New AI Test Predicting Response to Neoadjuvant Therapy in Breast Cancer

Ataraxis AI launched Ataraxis Breast NEO, a new predictive test within the Ataraxis Breast platform designed to estimate pathologic...

Apr 9, 2026

Ataraxis AI Launches Ataraxis Breast CTX, the First Predictive AI Test Estimating Individualized Chemotherapy Benefit in Breast Cancer

Business Wire

Ataraxis AI Launches Ataraxis Breast CTX, the First Predictive AI Test Estimating Individualized Chemotherapy Benefit in Breast Cancer

Ataraxis AI launched Ataraxis Breast CTX, a new predictive capability within the Ataraxis Breast platform, designed to estimate...

Mar 30, 2026

Ataraxis AI and Unicancer Partner to Validate Ataraxis Breast Prognostic Tool Using Global Phase III Trial Data

Business Wire

Ataraxis AI and Unicancer Partner to Validate Ataraxis Breast Prognostic Tool Using Global Phase III Trial Data

Ataraxis AI and Unicancer announced a strategic collaboration to validate Ataraxis AI's breast cancer platform using large-scale clinical...

Jan 6, 2026

Ataraxis AI to Present Eight Studies at SABCS 2025 Expanding Clinical Utility of Ataraxis Breast

Business Wire

Ataraxis AI to Present Eight Studies at SABCS 2025 Expanding Clinical Utility of Ataraxis Breast

Ataraxis AI announced it will present eight research abstracts with Ataraxis Breast data at the 2025 San Antonio Breast Cancer Symposium,...

Nov 18, 2025

Ataraxis AI to Transform Precision Medicine in Cancer Care with $20.4 Million Series A

Ataraxis AI

Ataraxis AI to Transform Precision Medicine in Cancer Care with $20.4 Million Series A

Ataraxis AI announced its $20.4 million Series A financing led by AIX Ventures with participation from Floating Point, Thiel Bio, Founders...

Mar 5, 2025